Viking's obesity pill VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in body ...

Novo is far from the only big pharma company bolstering DTC medicine offerings. Novo’s main rival in the GLP-1RA arena, Eli ...

CSL’s headcount reduction and vaccine spinoff dragged shares down 9.5%, from A$271.32 at market close on 18 August to ...

Santen has signed an agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein for retinal ...